Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

323 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Short term health-related quality of life improvement during opioid agonist treatment.
Nosyk B, Bray JW, Wittenberg E, Aden B, Eggman AA, Weiss RD, Potter J, Ang A, Hser YI, Ling W, Schackman BR. Nosyk B, et al. Among authors: weiss rd. Drug Alcohol Depend. 2015 Dec 1;157:121-8. doi: 10.1016/j.drugalcdep.2015.10.009. Epub 2015 Oct 25. Drug Alcohol Depend. 2015. PMID: 26511766 Free PMC article.
Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence.
Farrell M, Shahbazi J, Byrne M, Grebely J, Lintzeris N, Chambers M, Larance B, Ali R, Nielsen S, Dunlop A, Dore GJ, McDonough M, Montebello M, Nicholas T, Weiss R, Rodgers C, Cook J, Degenhardt L; CoLAB study team. Farrell M, et al. Int J Drug Policy. 2022 Feb;100:103492. doi: 10.1016/j.drugpo.2021.103492. Epub 2021 Nov 1. Int J Drug Policy. 2022. PMID: 34736130 Free article.
96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial.
Farrell M, Shahbazi J, Chambers M, Byrne M, Gholami J, Zahra E, Grebely J, Lintzeris N, Larance B, Ali R, Nielsen S, Dunlop A, Dore GJ, McDonough M, Montebello M, Weiss R, Rodgers C, Cook J, Degenhardt L; CoLAB study team. Farrell M, et al. Int J Drug Policy. 2024 May;127:104390. doi: 10.1016/j.drugpo.2024.104390. Epub 2024 Mar 23. Int J Drug Policy. 2024. PMID: 38522175 Free article.
Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trial.
Shulman M, Provost S, Ohrtman K, Novo P, Meyers-Ohki S, Van Veldhuisen P, Oden N, Otterstatter M, Bailey GL, Liu D, Rotrosen J, Nunes EV, Weiss RD. Shulman M, et al. Among authors: weiss rd. Contemp Clin Trials. 2024 Apr 23;142:107543. doi: 10.1016/j.cct.2024.107543. Online ahead of print. Contemp Clin Trials. 2024. PMID: 38657730
Effect of the Communities that HEAL intervention on receipt of behavioral therapies for opioid use disorder: A cluster randomized wait-list controlled trial.
Glasgow L, Douglas C, Sprunger JG, Campbell ANC, Chandler R, Dasgupta A, Holloway J, Marks KR, Roberts SM, Martinez LS, Thompson K, Weiss RD, Aldridge A, Asman K, Barbosa C, Blevins D, Chassler D, Cogan L, Fanucchi L, Hall ME, Hunt T, Jadovich E, Levin FR, Lincourt P, Lofwall MR, Loukas V, McAlearney AS, Nunes E, Oga E, Oller D, Rudorf M, Sullivan AM, Talbert J, Taylor A, Teater J, Vandergrift N, Woodlock K, Zarkin GA, Freisthler B, Samet JH, Walsh SL, El-Bassel N. Glasgow L, et al. Among authors: weiss rd. Drug Alcohol Depend. 2024 Jun 1;259:111286. doi: 10.1016/j.drugalcdep.2024.111286. Epub 2024 Apr 5. Drug Alcohol Depend. 2024. PMID: 38626553 Clinical Trial.
323 results